Mallinckrodt to sell UroCor prostate therapy:
This article was originally published in Clinica
Mallinckrodt will market and distribute UroCor's prostate cancer radiation therapy through its 35 nuclear medicine pharmacies, independent outlets and its group purchasing contracts. Oklahoma City, Oklahoma-based UroCor's ProstaSeed I-125 pellet device has gained US FDA 510(k) clearance and is awaiting clearance from the Nuclear Regulatory Commission for a launch later this year.
You may also be interested in...
The UK has approved the mRNA-based vaccine just nine days after receiving the final Phase III results from Pfizer.
As the MHRA prepares to grant approval to the Oxford/AstraZeneca vaccine, Wockhardt is set to supply 100 million doses for the UK government’s own use and its WHO commitments. The company is also in talks with global vaccine developers to manufacture their COVID-19 vaccines for emerging economies
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.